Satellos Bioscience

$MSLE News: Today we announced interim clinical and biomarker data for SAT-3247 at the @MDAorg Clinical & Scientific Conference in Orlando, Florida. Full details in our press release: tinyurl.com/3yybs7r9 #MDAConference #MDA2026 #MuscleRegeneration #Duchenne $MSCL

Greetings from Orlando! It’s day two at the 2026 @MDAorg conference, and the energy on the ground is outstanding. Our team is excited by the thoughtful conversations taking place and the shared commitment from the community here. If you’re at the conference, stop by Booth #116 to connect with us! #MDAconference #MDA #Duchenne #MuscleRegeneration $MSLE $MSCL

There are only two days until the start of the 2026 @MDAorg Clinical & Scientific Conference, and the Satellos team is preparing to present on SAT-3247 while there! Be sure to make time to visit us at Booth #116 to connect with the team and learn more about our novel approach to regenerating muscle from within. See you in Orlando! #MDA2026 #Duchenne #MuscleRegeneration #MDAConference $MSLE $MSCL

The Satellos team is excited to head to the 2026 @MDAorg Clinical & Scientific Conference next week in Orlando. While there, we will share two oral scientific presentations on SAT-3247 as well as three posters. See more detail on our full presence at #MDAConference below. To learn more about SAT-3247 and our science, please visit: satellos.com/science/ #MDA2026 #MuscleRegeneration #Duchenne $MSCL $MSLE

Thank you, @Steven38199694, for the thoughtful conversation with our CEO and Co-founder, Frank Gleeson. We appreciate the opportunity to discuss Satellos’ regenerative approach to #Duchenne muscular dystrophy and the progress of SAT-3247. Watch the full interview here:  youtube.com/watch?si=IZNKo… $MSLE $MSCL

At Satellos, we’re translating our discovery in #muscleregeneration into a new approach to treating #muscledisease. Because our work begins in #Duchenne muscular dystrophy, Rare Disease Day matters to our team. The bright green ribbon reflects the strength of the Duchenne community and the purpose behind our work. Today, we stand with the millions of individuals and families affected by rare diseases. We remain focused on advancing our research and turning it into real progress. Explore the science behind our work at satellos.com/science. #ResearchForRare #RareDiseaseDay2026

ICYMI: The replay of our recent SAT-3247 KOL event is now available. The webcast includes clinical updates, emerging biomarker insights, and scientific context supporting our regenerative approach in #Duchenne muscular dystrophy. Watch the replay: lifescievents.com/event/ld1kv6rj/ #MuscleRegeneration $MSLE $MSCL

Satellos is looking forward to the 2026 @MDAorg Clinical & Scientific Conference in Orlando, March 8–11. We’ll be sharing updates on SAT-3247 and our ongoing work to advance muscle regeneration for people living with degenerative muscle diseases. Full details here: tinyurl.com/3whuv96w #MDA2026 #Duchenne #MuscleRegeneration $MSLE $MSCL

Join Satellos and Kevin M. Flanigan, MD, Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine, for a discussion on the unmet need and evolving treatment landscape in #Duchenne muscular dystrophy. The event will include an overview of SAT-3247 and updates from the completed Phase 1 program, and the TRAILHEAD and BASECAMP Phase 2 studies. More details here: tinyurl.com/2mzwa7b8 📅 February 24, 2026 ⏰ 3:30 p.m. ET 💻 Virtual 🔗 Register: lifescievents.com/event/ld1kv6rj/ $MSLE $MSCL

Satellos will be connecting with investors over the next few weeks at the Oppenheimer, TD Cowen and Leerink Healthcare Conferences. Looking forward to sharing progress on SAT-3247, our clinical-stage therapy candidate focused on restoring muscle from within. More details here: tinyurl.com/43u2cxw2 #MuscleRegeneration #Duchenne $MSLE $MSCL

Great to be at @GuggSecurities Emerging Outlook: Biotech Summit 2026 today, connecting with investors and sharing more about Satellos’ work in #MuscleRegeneration. Thanks to everyone who took the time to connect. $MSCL $MSLE

Satellos announced today that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for #Duchenne muscular dystrophy. Full details here: tinyurl.com/569d37xm #MuscleRegeneration $MSCL $MSLE

Science is stronger with women in it. Today we celebrate the women at Satellos — and everywhere — whose curiosity, expertise and multi-processing skills are driving discovery and shaping the future. Here’s to the next generation of women and girls in science. #GirlsInScience #WomenInScience #STEM #EveryVoiceInScience $MSLE $MSCL

We’re excited to be on site at @TREAT_NMD 2026 as a proud sponsor of the neuromuscular community. If you’re here, come visit us at Booth #15. We’d love to connect and share more about our approach to #muscleregeneration. #TREATNMDConference26 $MSLE $MSCL

Satellos will be participating in a fireside chat at the @GuggSecurities Emerging Outlook: Biotech Summit 2026 in NYC on Feb. 12 at 10 a.m. ET. We look forward to sharing our recent progress and the momentum behind SAT-3247, our investigational therapy for people living with #Duchenne muscular dystrophy. Full details here: ir.satellos.com/news/news-deta… $MSLE $MSCL #MuscleRegeneration

Satellos announced today that its common shares have been approved for listing on the Nasdaq Stock Market LLC and have commenced trading under the ticker “MSLE.” The Company’s common shares continue to trade on TSX under “MSCL.” More here: tinyurl.com/5brx8yuw $MSLE $MSCL #MuscleRegeneration

We’re excited to welcome Antoinette Paone as Chief Development Officer & Head of Regulatory Affairs. Antoinette is an experienced development and regulatory leader with a strong track record across clinical development, regulatory strategy, and operational execution. She brings deep expertise spanning regulatory affairs, quality, CMC, technical operations, and program management. Read the full announcement: tinyurl.com/4xxehhc6 $MSCL $MSCLF